Kavita V Dharmarajan1, Debra L Friedman2, Cindy L Schwartz3, Lu Chen4, T J FitzGerald5, Kathleen M McCarten6, Sandy K Kessel5, Matt Iandoli5, Louis S Constine7, Suzanne L Wolden8. 1. Mount Sinai Medical Center, New York, New York. 2. Vanderbilt University, Nashville, Tennessee. 3. MD Anderson Cancer Center, Houston, Texas. 4. Children's Oncology Group, Arcadia, California. 5. Quality Assurance Review Center, Lincoln, Rhode Island. 6. Rhode Island Hospital/Warren Alpert Medical School at Brown University, Providence, Rhode Island. 7. University of Rochester Medical Center, Rochester, New York. 8. Memorial Sloan-Kettering Cancer Center, New York, New York. Electronic address: woldens@mskcc.org.
Abstract
PURPOSE: The study was designed to determine whether response-based therapy improves outcomes in intermediate-risk Hodgkin lymphoma. We examined patterns of first relapse in the study. PATIENTS AND METHODS: From September 2002 to July 2010, 1712 patients <22 years old with stage I-IIA with bulk, I-IIAE, I-IIB, and IIIA-IVA with or withoutdoxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide were enrolled. Patients were categorized as rapid (RER) or slow early responders (SER) after 2 cycles ofdoxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC). The SER patients were randomized to 2 additional ABVE-PC cycles or augmented chemotherapy with 21 Gy involved field radiation therapy (IFRT). RER patients were stipulated to undergo 2 additional ABVE-PC cycles and were then randomized to 21 Gy IFRT or no further treatment if complete response (CR) was achieved. RER without CR patients were non-randomly assigned to 21 Gy IFRT. Relapses were characterized without respect to site (initial, new, or both; and initial bulk or initial nonbulk), and involved field radiation therapy field (in-field, out-of-field, or both). Patients were grouped by treatment assignment (SER; RER/no CR; RER/CR/IFRT; and RER/CR/no IFRT). Summary statistics were reported. RESULTS: At 4-year median follow-up, 244 patients had experienced relapse, 198 of whom were fully evaluable for review. Those who progressed during treatment (n=30) or lacked relapse imaging (n=16) were excluded. The median time to relapse was 12.8 months. Of the 198 evaluable patients, 30% were RER/no CR, 26% were SER, 26% were RER/CR/no IFRT, 16% were RER/CR/IFRT, and 2% remained uncategorized. The 74% and 75% relapses involved initially bulky and nonbulky sites, respectively. First relapses rarely occurred at exclusively new or out-of-field sites. By contrast, relapses usually occurred at nodal sites of initial bulky and nonbulky disease. CONCLUSION: Although response-based therapy has helped define treatment for selected RER patients, it has not improved outcome for SER patients or facilitated refinement of IFRT volumes or doses.
RCT Entities:
PURPOSE: The study was designed to determine whether response-based therapy improves outcomes in intermediate-risk Hodgkin lymphoma. We examined patterns of first relapse in the study. PATIENTS AND METHODS: From September 2002 to July 2010, 1712 patients <22 years old with stage I-IIA with bulk, I-IIAE, I-IIB, and IIIA-IVA with or without doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide were enrolled. Patients were categorized as rapid (RER) or slow early responders (SER) after 2 cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC). The SERpatients were randomized to 2 additional ABVE-PC cycles or augmented chemotherapy with 21 Gy involved field radiation therapy (IFRT). RERpatients were stipulated to undergo 2 additional ABVE-PC cycles and were then randomized to 21 Gy IFRT or no further treatment if complete response (CR) was achieved. RER without CRpatients were non-randomly assigned to 21 Gy IFRT. Relapses were characterized without respect to site (initial, new, or both; and initial bulk or initial nonbulk), and involved field radiation therapy field (in-field, out-of-field, or both). Patients were grouped by treatment assignment (SER; RER/no CR; RER/CR/IFRT; and RER/CR/no IFRT). Summary statistics were reported. RESULTS: At 4-year median follow-up, 244 patients had experienced relapse, 198 of whom were fully evaluable for review. Those who progressed during treatment (n=30) or lacked relapse imaging (n=16) were excluded. The median time to relapse was 12.8 months. Of the 198 evaluable patients, 30% were RER/no CR, 26% were SER, 26% were RER/CR/no IFRT, 16% were RER/CR/IFRT, and 2% remained uncategorized. The 74% and 75% relapses involved initially bulky and nonbulky sites, respectively. First relapses rarely occurred at exclusively new or out-of-field sites. By contrast, relapses usually occurred at nodal sites of initial bulky and nonbulky disease. CONCLUSION: Although response-based therapy has helped define treatment for selected RERpatients, it has not improved outcome for SERpatients or facilitated refinement of IFRT volumes or doses.
Authors: Kara M Kelly; Richard Sposto; Raymond Hutchinson; Vickie Massey; Kathleen McCarten; Sherrie Perkins; Mark Lones; Doojduen Villaluna; Michael Weiner Journal: Blood Date: 2010-11-15 Impact factor: 22.113
Authors: W Dörffel; H Lüders; U Rühl; M Albrecht; H Marciniak; R Parwaresch; R Pötter; G Schellong; E-W Schwarze; L Wickmann Journal: Klin Padiatr Date: 2003 May-Jun Impact factor: 1.349
Authors: James B Nachman; Richard Sposto; Philip Herzog; Gerald S Gilchrist; Suzanne L Wolden; John Thomson; Marshall E Kadin; Paul Pattengale; P Charlton Davis; Raymond J Hutchinson; Keith White Journal: J Clin Oncol Date: 2002-09-15 Impact factor: 44.544
Authors: Karin Dieckmann; Richard Pötter; Johannes Hofmann; Harald Heinzl; Wolfgang Wagner; Günther Schellong Journal: Int J Radiat Oncol Biol Phys Date: 2003-07-01 Impact factor: 7.038
Authors: Cindy L Schwartz; Louis S Constine; Doojduen Villaluna; Wendy B London; Robert E Hutchison; Richard Sposto; Steven E Lipshultz; Charles S Turner; Pedro A deAlarcon; Allen Chauvenet Journal: Blood Date: 2009-07-07 Impact factor: 22.113
Authors: Sughosh Dhakal; Tithi Biswas; Jane L Liesveld; Jonathan W Friedberg; Gordon L Phillips; Louis S Constine Journal: Int J Radiat Oncol Biol Phys Date: 2009-02-26 Impact factor: 7.038
Authors: Thomas J FitzGerald; Maryann Bishop-Jodoin; David S Followill; James Galvin; Michael V Knopp; Jeff M Michalski; Mark A Rosen; Jeffrey D Bradley; Lalitha K Shankar; Fran Laurie; M Giulia Cicchetti; Janaki Moni; C Norman Coleman; James A Deye; Jacek Capala; Bhadrasain Vikram Journal: Int J Radiat Oncol Biol Phys Date: 2015-10-24 Impact factor: 7.038
Authors: Rahul R Parikh; Kara M Kelly; David C Hodgson; Bradford S Hoppe; Kathleen M McCarten; Katie Karolczuk; Qinglin Pei; Yue Wu; Steve Y Cho; Cindy Schwartz; Peter D Cole; Kenneth Roberts Journal: Int J Radiat Oncol Biol Phys Date: 2021-11-09 Impact factor: 7.038
Authors: Bradford S Hoppe; Raymond B Mailhot Vega; Nancy P Mendenhall; Eric S Sandler; William B Slayton; Howard Katzenstein; Michael J Joyce; Zuofeng Li; Stella Flampouri Journal: Int J Part Ther Date: 2020-04-27
Authors: James E Bates; Stephanie Terezakis; Christopher G Morris; Avani D Rao; Shuchi Sehgal; Rahul Kumar; Raymond B Mailhot Vega; Nancy P Mendenhall; Bradford S Hoppe Journal: Int J Part Ther Date: 2021-07-08
Authors: Matthew D Hall; Stephanie A Terezakis; John T Lucas; Eve Gallop-Evans; Karin Dieckmann; Louis S Constine; David Hodgson; Jamie E Flerlage; Monika L Metzger; Bradford S Hoppe Journal: Int J Radiat Oncol Biol Phys Date: 2021-08-12 Impact factor: 7.038
Authors: B S Hoppe; C E Hill-Kayser; Y D Tseng; S Flampouri; H M Elmongy; O Cahlon; N P Mendenhall; A Maity; L A McGee; J P Plastaras Journal: Ann Oncol Date: 2017-09-01 Impact factor: 32.976